Citations

Clear

6274 citation(s) found for "To, Andrew".

Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603)
Guerard, Emily J., Dodge, Andrew , Le‐Rademacher, Jennifer , Kemeny, Margaret, Ojelabi, Michael, Sedrak, Mina S. , Hopkins, Judith O. , Shahrokni, Armin , Harlos, Elizabeth, Muss, Hyman B. , Cohen, Harvey Jay, Lafky, Jacqueline M., Sloan, Jeff A. , Jatoi, Aminah , Hurria, Arti , Dodge, Andrew B , Le-Rademacher, Jennifer G , Muss, Hyman , Lafky, Jacqueline, Sloan, Jeff , Ojelabi, Michael Olayiwola , Sedrak, Mina S.

Mayo Clinic

JCO Clinical Cancer Informatics | April 14, 2021 | Volume: No volume available | Issue: 5 | Pages: 435-441

10.1200/cci.20.00163 | PMID 33852323 Get It

PURPOSE This study determined whether an electronic version of the geriatric assessment is feasible in a multi-institutional, diverse setting. METHODs Ten sites within the Alliance for Clinical Trials in Oncology participated. Patients who had active cancer or a history of cancer and were 65 years of age or older were eligible. The geriatric assessment was completed with an electronic data capture system that had been loaded onto iPads. Feasibility was defined a priori as completion in at least 70% of patients either with or without help. To enhance racial diversity, the original sample size was later changed and augmented by 50% with the intention of increasing enrollment of older minority patients. RESULTS A total of one hundred fifty-four patients were registered with a median age of 72 years (range, 65-91 years). Forty-three (28%) identified themselves as African American or Black. One hundred forty-one patients (92%) completed the electronic geriatric assessment. Feasibility was observed across all subgroups, regardless of race, education, performance status, comorbidities, and cognition; 124 patients (81%) completed the geriatric assessment without help. Reasons for not completing the geriatric assessment are as follows: clinic visit did not occur (n = 6), no iPad connection to the Internet (n = 3), patient declined (n = 2), prolonged hospitalization (n = 1), and patient died (n = 1). Reasons for needing help, as reported by study personnel, were as follows: the patient preferred that research personnel ask the questions (n = 9), vision problem (n = 3), lack of comfort with the iPad (n = 2), questions were not clear (n = 1), less proficient in English (n = 1), and challenge in pressing the green button to go to the next question (n = 1). CONCLUSION The electronic geriatric assessment is feasible in a multi-institutional setting that includes a notable proportion of African American or Black patients.
Clinical efficacy and safety of magnetic sphincter augmentation (MSA) and transoral incisionless fundoplication (TIF2) in refractory gastroesophageal reflux disease (GERD): a systematic review and meta-analysis
Khan, Shahab R. , Jha, Lokesh K. , Dhaliwal, Amaninder J., Aziz, Muhammad , Arora, Sumant, Malik, Sarah , Kassab, Lena L., Ponnada, Suresh, Bhat, Ishfaq , Hewlett, Alexander , McDonough, Stephanie, Chandan, Saurabh , Mohan, Babu P. , Bilal, Mohammad , Canakis, Andrew , Sharma, Neil, Adler, Douglas G.

Mayo Clinic

Endoscopy International Open | April 14, 2021 | Volume: 09 | Issue: 04 | Pages: E583-E598

10.1055/a-1352-2944 | PMID 33869732 Get It

Abstract Background and study aims Proton pump inhibitors (PPI) are effective medical therapy options for gastro-esophageal reflux disease (GERD). However, 20 % to 40 % of patients report symptoms despite taking daily PPI. Transoral incisionless fundoplication (TIF2) and magnetic sphincter augmentation (MSA) are less invasive options for the treatment of refractory GERD and are increasingly gaining popularity. Methods We conducted a comprehensive search of several databases to identify relevant studies. Our primary aim was to compare the efficacy of both interventions reported as improvement in Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score, overall patient satisfaction, improvement in post-procedure regurgitation, and fraction of patients completely off PPI therapy at follow up. Results Twenty-four studies with 1942 patients were included in the final analysis. Both MSA and TIF2 had comparable technical success and clinical success based on improvement in GERD-HRQL scores i. e. 98.8 % (CI 95.6,99.7) vs 98.5 % (CI 95.7,99.5) and 80.4 % (CI 66,89.6) vs 77.7 % (CI 64.1,87.2), respectively. A significantly greater proportion of patients reported improvement in regurgitation, i. e. 91.1 % (CI 83.8,95.3) vs 73.1 % (CI 62.5,81.7) and were able to completely discontinue PPI therapy with MSA compared to TIF2 i. e. 91.3 % (CI 81.5,96.2) vs 63.8 % (CI 51.6,74.4). Patients’ BMI and presence of a hiatal hernia did not have any effect on procedural outcomes. Conclusion Both procedures performed at par when comparing clinical success in terms of improvement in GERD-HRQL scores. In terms of overall patient satisfaction, post procedure regurgitation and cumulative number of patients off PPI therapy, MSA outperforms TIF2.
MRI Study of Jellyfish Collagen, Hyaluronic Acid, and Cadaveric Dermis for Injection Laryngoplasty
San‐Marina, Serban , Oldenburg, Michael , Voss, Stephen G. , Hunter, Danielle E., Meloche, Ryan , Miller, Alen Lee, Spragg, Andrew Mearns, Ekbom, Dale C. , Oldenburg, Michael S , Voss, Stephen , Macura, Slobodan , Ekbom, Dale , Bowen, Andrew J.

Mayo Clinic

The Laryngoscope | April 14, 2021 | Volume: 131 | Issue: 8 | Pages: No page available

10.1002/lary.29501 | PMID 33847388 Get It

AbstractObjectives/HypothesisTest a new jellyfish collagen biomaterial aimed to increase duration of injection medialization laryngoplasty (IL) against two products in clinical practice.Study DesignAnimal model.MethodsLeft recurrent laryngeal nerve sectioning and IL were performed in New Zealand White rabbits (N = 6/group). Group 1 received micronized cross‐linked jellyfish collagen (MX‐JC) and adipose derived stem cells (ADSCs), Group 2, MX‐JC alone, Group 3, cross‐linked hyaluronic acid (X‐HA), and Group 4, micronized acellular dermis (MACD). Animals were sacrificed at 4 and 12 weeks. Major outcomes were MRI tissue volumes and histopathology.ResultsAfter 100 μL IL MRI volumes (means ± STD) at 4 and 12 weeks were: Group 1: 27.2 ± 15.6 and 13.1 ± 5.2 μL, Group 2: 60.8 ± 18 and 27.8 ± 2.47 μL, Group 3: 27.4 ± 12 and 10.6 ± 8 μL, and Group 4: 37.5 ± 11 and 9.85 ± 1 μL. Group 2 volumes were largest and Group 3 were smallest in all comparisons (P < .05). Histologically, low grade inflammatory responses were observed in Group 1, mild histiocytic infiltration in Group 2, widespread muscle fiber loss in Group 3, and plasmocytic infiltration in Group 4.ConclusionsMX‐JC showed the least resorption at 4 and 12 weeks among all groups. T cell inflammatory responses were observed with MX‐JC but were reduced by 12 weeks while B cell immune responses, indicative of antibody priming, were predominantly noted with MACD. MX‐JC + ADSC showed low grade immunity while the XHA showed greater myocyte loss compared to the other groups.Level of EvidenceNA Laryngoscope, 131:E2452–E2460, 2021
A standard system phantom for magnetic resonance imaging
Stupic, Karl F. , Ainslie, Maureen, Boss, Michael A. , Charles, Cecil, Dienstfrey, Andrew , Evelhoch, Jeffrey L., Finn, Paul, Gimbutas, Zydrunas , Gunter, Jeffrey L. , Hill, David , Karaulanov, Todor , Liu, Guoying , Martin, Michele N. , Prasad, Pottumarthi V. , Rentz, Nikki S., Yuan, Chun , Keenan, Kathryn E , Yuan, Chun , Russek, Stephen E , Boss, Michael A , Jack, Clifford R. , Jackson, Edward F. , Keenan, Kathryn E. , Russek, Stephen E.

Mayo Clinic

Magnetic Resonance in Medicine | April 13, 2021 | Volume: 86 | Issue: 3 | Pages: 1194-1211

10.1002/mrm.28779 | PMID 33847012 Get It

Purpose A standard MRI system phantom has been designed and fabricated to assess scanner performance, stability, comparability and assess the accuracy of quantitative relaxation time imaging. The phantom is unique in having traceability to the International System of Units, a high level of precision, and monitoring by a national metrology institute. Here, we describe the phantom design, construction, imaging protocols, and measurement of geometric distortion, resolution, slice profile, signal‐to‐noise ratio (SNR), proton‐spin relaxation times, image uniformity and proton density. Methods The system phantom, designed by the International Society of Magnetic Resonance in Medicine ad hoc committee on Standards for Quantitative MR, is a 200 mm spherical structure that contains a 57‐element fiducial array; two relaxation time arrays; a proton density/SNR array; resolution and slice‐profile insets. Standard imaging protocols are presented, which provide rapid assessment of geometric distortion, image uniformity, T 1 and T 2 mapping, image resolution, slice profile, and SNR. Results Fiducial array analysis gives assessment of intrinsic geometric distortions, which can vary considerably between scanners and correction techniques. This analysis also measures scanner/coil image uniformity, spatial calibration accuracy, and local volume distortion. An advanced resolution analysis gives both scanner and protocol contributions. SNR analysis gives both temporal and spatial contributions. Conclusions A standard system phantom is useful for characterization of scanner performance, monitoring a scanner over time, and to compare different scanners. This type of calibration structure is useful for quality assurance, benchmarking quantitative MRI protocols, and to transition MRI from a qualitative imaging technique to a precise metrology with documented accuracy and uncertainty.
Gastrointestinal defect closure using a novel through-the-scope helix tack and suture device compared to endoscopic clips in a survival porcine model (with video)
Hernandez, Ariosto, Marya, Neil B. , Sawas, Tarek , Rajan, Elizabeth , Gades, Naomi M. , Song, Louis M. Wong Kee , Buttar, Navtej , Wong Kee Song, Louis M, Hernandez, Ariosto, Marya, Neil B. , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | April 12, 2021 | Volume: 09 | Issue: 04 | Pages: E572-E577

10.1055/a-1370-9256 | PMID 33860074 Get It

Abstract Background and aims Endoscopic resections are associated with bleeding and perforation and may be managed with through-the-scope (TTS) clips, over-the-scope clips and endoscopic suturing. The aim of this preclinical study was to compare technical success of closure using a novel TTS tissue helix tack and suture device (X-Tack) to TTS clips in a porcine model. Materials and methods Four subjects underwent 40 mucosal resections, diameter range 25–50 mm, in the stomach (n = 24) and colon (n = 16). Closures were randomized to X-Tack (n = 24) or clip (n = 16). Animals underwent weekly endoscopic follow-up for 4 weeks. Results Technical closure with X-Tack was successful in 24 of 24 (100 %) cases and with clips in 13 of 16 cases (81.3 %) (P = 0.0001). One colonic perforation occurred and was successfully managed using X-Tack. The rate of healing was not statistically different between the groups, and all sites healed at 4 weeks including the perforation and were confirmed by histology. Conclusions Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. There was no difference in rate of healing between devices.
Effectiveness and Safety of EUS Rendezvous After Failed Biliary Cannulation With ERCP
Klair, Jagpal S. , Zafar, Yousaf , Ashat, Munish , Bomman, Shivanand , Jayaraj, Mahendran , Law, Joanna K. , Larsen, Michael , Singh, Dhruv P. , Rustagi, Tarun , Irani, Shayan , Ross, Andrew , Kozarek, Richard A. , Krishnamoorthi, Rajesh , Murali, Arvind R.

Mayo Clinic

Journal of Clinical Gastroenterology | April 9, 2021 | Volume: 57 | Issue: 2 | Pages: 211-217

10.1097/mcg.0000000000001543 | PMID 34009843 Get It

Background: Endoscopic ultrasound–guided rendezvous (EUS-RV) endoscopic retrograde cholangiopancreatography (ERCP) is an alternative to interventional radiology–guided rendezvous ERCP in patients who failed biliary cannulation with conventional ERCP. However, there is significant variation in reported rates of success and adverse events associated with EUS-RV-assisted ERCP. We performed a systematic review and a proportion meta-analysis to reliably assess the effectiveness and safety of the EUS-RV-assisted ERCP. Materials and Methods: We conducted a comprehensive search of multiple electronic databases and conference proceedings (from inception through August 2020) to identify studies reporting EUS-RV-assisted ERCP in patients who failed biliary cannulation with conventional ERCP techniques. Using the random-effects model described by DerSimonian and Laird, we calculated the pooled rates of technical success, clinical success, and adverse events of EUS-RV-assisted ERCP. Results: Twelve studies reporting a total of 342 patients were included in the meta-analysis. The pooled rate of technical success (12 studies reporting a total of 342 patients) was 86.1% [95% confidence interval (CI): 78.4-91.3]. The pooled rate of clinical success (4 studies reporting a total of 94 patients) was 80.8% (95% CI: 64.1-90.8). The pooled rate of overall adverse events (12 studies; 42 events in 342 patients) was 14% (95% CI: 10.5-18.4). Low to moderate heterogeneity was noted in the analyses. Conclusions: EUS-RV-assisted ERCP appears to be effective and safe in patients who failed biliary cannulation with conventional ERCP. Given the risk of adverse events, it should be performed in centers with expertise in therapeutic endoscopic ultrasound.
Effect of combined renin angiotensin aldosterone inhibitors and diuretic treatment among patients hospitalized with SARS-CoV-2 Infection COVID-19
Palazzuoli, Alberto , Tecson, Kristen M. , Vicenzi, Marco , D’Ascenzo, Fabrizio, Ferrari, Gaetano Maria De , Monticone, Silvia , Secco, Gioel Gabrio , Tavazzi, Guido , Forleo, Giovanni B. , Severino, Paolo , Fedele, Francesco G. , Rosa, Francesco Giuseppe De , McCullough, Peter Andrew

Mayo Clinic

No container title available | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-345834/v1 Get It

Abstract Background: Antecedent use of renin angiotensin aldosterone inhibitors (RAASi) appears crucial to prevent clinical deterioration and protect against cardiovascular and/or thrombotic complications of Coronavirus Disease (COVID-19), for indicated patients. Doubts have been raised about continuing treatment throughout infection, and nothing is known regarding its effect with concomitant medications. Hence, the purpose of this paper is to evaluate the differential effect of RAASi continuation in patients hospitalized with COVID-19 according to diuretic use.Methods: We used the Coracle (epidemiology, clinical characteristics, and therapy in real life patients affected by Sars-Cov-2) multi-center registry, which contains data of hospitalized patients with COVID-19 from 4 regions of Italy. We performed analyses on adult (50+ years) records with admission on/after February 22, 2020 with a known mortality or discharge status as of April 1, 2020. We constructed a multivariable Firth logistic regression model to complete our objective.Results: There were 286 patients in this analysis. Overall, 100 (35.0%) patients continued RAASi and 186 (65%) discontinued. There were 98 patients who were treated with a diuretic; 51 (52%) of those continued RAASi. The in-hospital mortality rates among patients treated with a diuretic and continued vs. discontinued RAASi were 7.8% vs 25.5% (p = 0.0179). There were 188 patients who were not treated with a diuretic; 49 (26.1%) of those continued RAASi. The in-hospital mortality rates among patients who were not treated with a diuretic and continued vs. discontinued RAASi were 16.3% vs 9.4% (p = 0.1827). After accounting for age, congestive heart failure, and coronary heart disease/ischemic heart disease, continuing RAASi decreased the risk of mortality by approximately 72% (OR = 0.28, 95% CI = 0.08 – 0.94, p = 0.0391) for patients treated with diuretics, but did not alter the risk in patients who were not treated with diuretics.Conclusion: Diuretic use in hospitalized patients with COVID-19 who were on RAASi prior to admission was associated with increased risk of in-hospital mortality. Whether this combined therapy increases risk or is the reflection of a more severe presentation deserves further investigation. Continuing RAASi therapy in patients concomitantly treated with diuretics was associated with reduced in-hospital mortality.
A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
Mukaddam, Mona Al , Stockklausner, Clemens , Pignolo, RJ, Brown, MA, Cunto, Carmen De , Rocco, M Di, Hsiao, EC, Sang, K-H Le Quan, Strahs, Andrew , Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Rocco, M Di, Keen, Richard

Mayo Clinic

Osteologie | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1722141 Get It

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Choueiri, Toni K. , Zakharia, Yousef , Pal, Sumanta K. , Kocsis, Judit , Pachynski, Russell K. , Poprach, Alexandr , Starr, Mark D. , Owzar, Kouros , deShazo, Mollie, Lara, Primo N. , Géczi, Lajos , Ho, Thai H. , Walsh, Meghara , Adams, Bonne J., Robertson, Liz, Darif, Mohamed, Theuer, Charles P. , Ho, Thai , Choueiri, Toni K , Pachynski, Russell K , Zakharia, Yousef , Nixon, Andrew B. , Liu, Yingmiao , Lyu, Jing, Agarwal, Neeraj

Mayo Clinic

The Oncologist | April 8, 2021 | Volume: 26 | Issue: 7 | Pages: 560-e1103

10.1002/onco.13777 | PMID 33829609 Get It

Abstract Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors. Methods TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 Results A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. Conclusion The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.
Per pass analysis of thrombus composition retrieved by mechanical thrombectomy
Abbasi, Mehdi , Kvamme, Peter , Patel, Biraj M. , Gounis, Matthew J. , Kadirvel, Ramanathan , Kallmes, David F. , Doyle, Karen , Cloft, Harry J. , Liu, Yang , Thacker, Ike, Aghaebrahim, Amin, Sauvageau, Eric , Copelan, Alexander , Nazari, Pouya , Cantrell, Donald R. , Bhuva, Parita, Soomro, Jazba , Mohammaden, Mahmoud , Pisani, Leonardo , Puri, Ajit S , Brinjikji, Waleed , Patel, Biraj M , Fitzgerald, Seán , Mereuta, Oana M, Dai, Daying , Kadirvel, Ram , Kallmes, David F , Savastano, Luis E., Kayan, Yasha , Nazari, Pouya , Al-Bayati, Alhamza , Brinjikji, Waleed , Liu, Yang , Layton, Kennith F. , Hanel, Ricardó A. , Almekhlafi, Mohammed , Almandoz, Josser E Delgado , Mendes Pereira, Vitor , Jahromi, Babak S. , Yoo, Albert J. , Nogueira, Raul G. , Fitzgerald, Seán , Mereuta, Oana Madalina , Dai, Daying , Savastano, Luis , Demchuk, Andrew M. , Entwistle, John, Haussen, Diogo C , Al‐Bayati, Alhamza R , Rodrigues, Gabriel Martins

Mayo Clinic

Interventional Neuroradiology | April 7, 2021 | Volume: 27 | Issue: 6 | Pages: 815-820

10.1177/15910199211009119 | PMID 33823621 Get It

Background and aim Mechanical thrombectomy (MT) for large vessel occlusion often requires multiple passes to retrieve the entire thrombus load. In this multi-institutional study we sought to examine the composition of thrombus fragments retrieved with each pass during MT. Methods Patients who required multiple passes during thrombectomy were included. Histopathological evaluation of thrombus fragments retrieved from each pass was performed using Martius Scarlet Blue staining and the composition of each thrombus component including RBC, fibrin and platelet was determined using image analysis software. Results 154 patients underwent MT and 868 passes was performed which resulted in 263 thrombus fragments retrieval. The analysis of thrombus components per pass showed higher RBC, lower fibrin and platelet composition in the pass 1 and 2 when compared to pass 3 and passes 4 or more combined (P values <0.05). There were no significant differences between thrombus fragments retrieved in pass 1 and pass 2 in terms of RBC, WBC, fibrin, and platelet composition (P values >0.05). Similarly, when each composition of thrombus fragments retrieved in pass 3 and passes 4 or more combined were compared with each other, no significant difference was noted (P values >0.05). Conclusion Our findings confirm that thrombus fragments retrieved with each pass differed significantly in histological content. Fragments in the first passes were associated with lower fibrin and platelet composition compared to fragments retrieved in passes three and four or higher. Also, thrombus fragments retrieved after failed pass were associated with higher fibrin and platelet components.